
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G

**Under the Securities Exchange Act of 1934
(Amendment No.)***

Cargo Therapeutics, Inc.

(Name of Issuer)

Common stock, \$0.001 par value per share

(Title of Class of Securities)

14179K 10 1

(CUSIP Number)

November 14, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of Reporting Persons Nextech VII Oncology SCSp	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/> (1)	
3.	SEC Use Only	
4.	Citizenship or Place of Organization Luxembourg	
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 2,642,502 shares
	6.	Shared Voting Power 0
	7.	Sole Dispositive Power 2,642,502 shares
	8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,642,502 shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 6.8% (2)	
12.	Type of Reporting Person (See Instructions) PN	

(1) This Schedule 13G is filed by Nextech VII Oncology SCSp (“Nextech VII LP”), Nextech VII GP S.à. r.l. (“Nextech VII GP”), Ian Charoub, (“Charoub”), Costas Constantinides (“Constantinides”) and Rocco Sgobbo (“Sgobbo” and, with Nextech VII LP, Nextech VII GP, Charoub and Constantinides, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) This percentage is calculated based on 38,672,544 shares of Common Stock outstanding as of November 14, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus dated November 9, 2023 filed by the Issuer with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

1.	Names of Reporting Persons Nextech VII GP S.à. r.l.	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/> (1)	
3.	SEC Use Only	
4.	Citizenship or Place of Organization Luxembourg	
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 2,642,502 shares
	6.	Shared Voting Power 0
	7.	Sole Dispositive Power 2,642,502 shares
	8.	Shared Dispositive Power 0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,642,502 shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 6.8% (2)	
12.	Type of Reporting Person (See Instructions) OO	

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
- (2) This percentage is calculated based on 38,672,544 shares of Common Stock outstanding as of November 14, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus dated November 9, 2023 filed by the Issuer with the SEC on November 13, 2023.

1.	Names of Reporting Persons Ian Charoub	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/> (1)	
3.	SEC Use Only	
4.	Citizenship or Place of Organization Sweden	
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 2,642,502 shares
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 2,642,502 shares
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,642,502 shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 6.8% (2)	
12.	Type of Reporting Person (See Instructions) IN	

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
- (2) This percentage is calculated based on 38,672,544 shares of Common Stock outstanding as of November 14, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus dated November 9, 2023 filed by the Issuer with the SEC on November 13, 2023.

1.	Names of Reporting Persons Costas Constantinides	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/> (1)	
3.	SEC Use Only	
4.	Citizenship or Place of Organization Cyprus	
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 2,642,502 shares
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 2,642,502 shares
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,642,502 shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 6.8% (2)	
12.	Type of Reporting Person (See Instructions) IN	

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
- (2) This percentage is calculated based on 38,672,544 shares of Common Stock outstanding as of November 14, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus dated November 9, 2023 filed by the Issuer with the SEC on November 13, 2023.

1.	Names of Reporting Persons Rocco Sgobbo	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/> (1)	
3.	SEC Use Only	
4.	Citizenship or Place of Organization Switzerland	
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 0
	6.	Shared Voting Power 2,642,502 shares
	7.	Sole Dispositive Power 0
	8.	Shared Dispositive Power 2,642,502 shares
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,642,502 shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 6.8% (2)	
12.	Type of Reporting Person (See Instructions) IN	

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
- (2) This percentage is calculated based on 38,672,544 shares of Common Stock outstanding as of November 14, 2023 upon the closing of the Issuer’s public offering, as reported in the prospectus dated November 9, 2023 filed by the Issuer with the SEC on November 13, 2023.

Item 1.

- (a) Name of Issuer
Cargo Therapeutics, Inc.
-
- (b) Address of Issuer's Principal Executive Offices
1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA 94403
-

Item 2.

- (a) Name of Person Filing
Nextech VII Oncology SCSp ("Nextech VII LP")
Nextech VII GP S.à. r.l. ("Nextech VII GP")
Ian Charoub ("Charoub")
Costas Constantinides ("Constantinides")
Rocco Sgobbo ("Sgobbo")
-
- (b) Address of Principal Business Office or, if none, Residence
8 rue Lou Hemmer
L-1748 Luxembourg-Findel
Grand-Duché de Luxembourg
-
- (c) Citizenship

<u>Name</u>	<u>Citizenship or Place of Organization</u>
Nextech VII LP	Luxembourg
Nextech VII GP	Luxembourg
Charoub	Sweden
Constantinides	Cyprus
Sgobbo	Switzerland

- (d) Title of Class of Securities
Common Stock, \$0.001 par value ("Common Stock")
-
- (e) CUSIP Number
14179K 10 1
-

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 21, 2023:

Reporting Persons	Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (2)
Nextech VII LP (1)	2,642,502	2,642,502	0	2,642,502	0	2,642,502	6.8%
Nextech VII GP (1)	0	2,642,502	0	2,642,502	0	2,642,502	6.8%
Charoub (1)	0	0	2,642,502	0	2,642,502	2,642,502	6.8%
Constantinides (1)	0	0	2,642,502	0	2,642,502	2,642,502	6.8%
Sgobbo (1)	0	0	2,642,502	0	2,642,502	2,642,502	6.8%

- (1) The shares are held by Nextech VII LP. Nextech VII GP serves as the sole general partner of Nextech VII LP and has sole voting and investment control over the shares owned by Nextech VII LP and may be deemed to own beneficially the shares held by Nextech VII LP. Nextech VII GP owns no securities of the Issuer directly. Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech VII GP and share voting and dispositive power over the shares held by Nextech VII LP, and may be deemed to own beneficially the shares held by Nextech VII LP. Charoub, Constantinides and Sgobbo own no securities of the Issuer directly.
- (2) This percentage is calculated based on 38,672,544 shares of Common Stock outstanding as of November 14, 2023 upon the closing of the Issuer's public offering, as reported in the prospectus dated November 9, 2023 filed by the Issuer with the SEC on November 13, 2023.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 21, 2023

Nextech VII Oncology SCSp

By: Nextech VII GP S.à. r.l.
its General Partner

By: /s/ Ian Charoub
Name: Ian Charoub
Title: Manager

By: /s/ Costas Constantinides
Name: Costas Constantinides
Title: Manager

Nextech VII GP S.à. r.l.

By: /s/ Ian Charoub
Name: Ian Charoub
Title: Manager

By: /s/ Costas Constantinides
Name: Costas Constantinides
Title: Manager

/s/ Ian Charoub
Ian Charoub

/s/ Costas Constantinides
Costas Constantinides

/s/ Rocco Sgobbo
Rocco Sgobbo

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

Exhibit(s):

A Joint Filing Agreement

EXHIBIT A

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Cargo Therapeutics, Inc. is filed on behalf of each of us.

Dated: November 21, 2023

Nextech VII Oncology SCSp

By: Nextech VII GP S.à. r.l.
its General Partner

By: /s/ Ian Charoub

Name: Ian Charoub
Title: Manager

By: /s/ Costas Constantinides

Name: Costas Constantinides
Title: Manager

Nextech VII GP S.à. r.l.

By: /s/ Ian Charoub

Name: Ian Charoub
Title: Manager

By: /s/ Costas Constantinides

Name: Costas Constantinides
Title: Manager

/s/ Ian Charoub

Ian Charoub

/s/ Costas Constantinides

Costas Constantinides

/s/ Rocco Sgobbo

Rocco Sgobbo
